Category: Psychedelic Bulletin - Psychedelic Alpha

Introducing Pα+: learn more and subscribe today.

Read more about the article Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates

Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates

Post published:November 29, 2023
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments

Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments

Post published:November 17, 2023
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Bulletin #148 (Pα+)

Psychedelic Bulletin #148 (Pα+)

Post published:November 3, 2023
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Bulletin #147: Newsom Vetoes Psychedelic Decrim. in CA; At-Home Ketamine Gets a Lifeline and a Warning; Drug Development Updates from GH, atai, Cybin; and more

Psychedelic Bulletin #147: Newsom Vetoes Psychedelic Decrim. in CA; At-Home Ketamine Gets a Lifeline and a Warning; Drug Development Updates from GH, atai, Cybin; and more

Post published:October 17, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective Alongside SSRI; Preprint Calls Intracellular Theory of Psychedelic-induced Neuroplasticity Into Question; A Cole Memo for Psychedelics?

Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective Alongside SSRI; Preprint Calls Intracellular Theory of Psychedelic-induced Neuroplasticity Into Question; A Cole Memo for Psychedelics?

Post published:September 29, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor

Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor

Post published:September 19, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft Guidance; Cybin to Acquire Small Pharma; Usona Publishes Phase 2 Study

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft Guidance; Cybin to Acquire Small Pharma; Usona Publishes Phase 2 Study

Post published:August 31, 2023
Post category:Psychedelic Bulletin

Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection

Post published:August 11, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #142: Terran’s IP Portfolio; AMA Advocates Against Non-Medical Psychedelics; Couple Receives First Psilocybin Services in Oregon; Mass. Ballot Measure Ramps Up; NIDA and NIMH Directors Opine

Psychedelic Bulletin #142: Terran’s IP Portfolio; AMA Advocates Against Non-Medical Psychedelics; Couple Receives First Psilocybin Services in Oregon; Mass. Ballot Measure Ramps Up; NIDA and NIMH Directors Opine

Post published:July 31, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #141: Terran’s 4-OH-DiPT Prodrug Patent App.; Generic Ketamine Appears Effective for TRD; VA/DoD Guideline Reviews Psychedelics

Psychedelic Bulletin #141: Terran’s 4-OH-DiPT Prodrug Patent App.; Generic Ketamine Appears Effective for TRD; VA/DoD Guideline Reviews Psychedelics

Post published:July 17, 2023
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.